Latest Compugen News & Updates

See the latest news and media coverage for Compugen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Compugen

Clinical-stage biotechnology company developing immuno-oncology therapeutics

cgen.com

Headquarters: Holon, Israel
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated October 5

Latest news about Compugen

In short: Compugen launched UnigenX AI for cancer target discovery and advanced its COM701 ovarian trial while reporting Q2 2026 results.

Company announcements

August 3 Compugen

Compugen reports Q2 2026 financial results and clinical progress

MAIA-ovarian interim PFS data expected by Q1 2027; AstraZeneca presented rilvegostomig OS data; Gilead-partnered GS-0321 Phase 1 progresses; cash runway into 2029.

July 20 Compugen

Compugen to release second quarter 2026 results on August 3

The company will host a conference call and webcast at 8:30 AM ET to review the results and provide a corporate update.

May 18 Compugen

Compugen reported Q1 2026 financial results and pipeline progress

Cash runway extends into 2029; COM701 MAIA-ovarian trial actively enrolling; partners AstraZeneca and Gilead advancing programs.

March 2 Compugen

Compugen reports Q4 and full year 2025 results

Strengthened financial position via AstraZeneca deal and advanced clinical pipeline with COM701 and GS-0321.

Media coverage

October 5 MarketScreener

Transcript : Compugen Ltd. - Special Call

Good morning, everyone, and welcome to Compugen's COM701 in ovarian cancer and UNIGEN platform update event. [Operator Instructions] Before handing the...

October 5 Yahoo Finance

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets

Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive...

August 3 Zone Bourse

Compugen Ltd. Reports Results for the Second Quarter and First Half Ended June 30, 2026

Compugen Ltd. announced its financial results for the second quarter and first half ended June 30, 2026. For the second quarter, the...

August 3 The Globe and Mail

Compugen Posts Q2 2026 Results as Key Cancer Immunotherapy Trials Advance

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities...

Never miss news about Compugen

Track Compugen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Compugen competitors & trending companies

Browse news for competitors to Compugen and other trending companies.